{"id":7680,"date":"2023-05-02T09:25:01","date_gmt":"2023-05-02T08:25:01","guid":{"rendered":"https:\/\/www.afmb.univ-mrs.fr\/?post_type=event&p=7680"},"modified":"2023-05-02T17:06:33","modified_gmt":"2023-05-02T16:06:33","slug":"directors-guest-xavier-morelli-crcm-ipc-marseille-mixing-drug-repositioning-with-fragment-based-drug-design-approaches-to-tackle-acute-lymphoblastic-leukemia-t-allinvite-direction-xavier-m","status":"publish","type":"event","link":"https:\/\/www.afmb.univ-mrs.fr\/en\/event\/directors-guest-xavier-morelli-crcm-ipc-marseille-mixing-drug-repositioning-with-fragment-based-drug-design-approaches-to-tackle-acute-lymphoblastic-leukemia-t-allinvite-direction-xavier-m\/","title":{"rendered":"Director’s guest: Xavier Morelli, CRCM, IPC Marseille – “Mixing Drug Repositioning with Fragment-Based Drug Design Approaches to Tackle Acute Lymphoblastic Leukemia (T-ALL)”"},"content":{"rendered":"\n

Abstract<\/h2>\n\n\n\n

The discovery & development of new drugs is a highly costly and slow process, while repositioning old drugs to treat other diseases is increasingly becoming an attractive proposition1<\/sup>. In this context and at the interface between drug repositioning and drug design, we have applied our integrative multidisciplinary fragment-based drug design approach, \u2018DOTS\u2019. We have deconstructed an existing drug -masitinib- originally targeting a protein tyrosine kinase, c-kit, and (re)optimized it against a new target, the deoxycytidine kinase (dCK), a nucleotide kinase involved in the pyrimidine biosynthesis (salvage) pathway. Our lead compound -OR0642- in combination with a physiological inhibitor of the de novo<\/em> pathway, deoxythymidin (dT), doubled the survival rate in a human T-cell Acute Lymphoblastic Leukemia patient-derived xenograft mouse model, demonstrating the proof-of-concept<\/em> of this mixed strategy2<\/sup>.<\/p>\n\n\n\n

————————————————————————–<\/p>\n\n\n\n

1- Hammam K, Saez-Ayala M et al. Nature Communications 2017. (PMID 29127277)<\/em><\/p>\n\n\n\n

2- Saez-Ayala M et al. Nature Communications, in press.<\/em><\/p>\n","protected":false},"template":"","events_category":[16],"class_list":["post-7680","event","type-event","status-publish","hentry","events_category-webinar","entry"],"_links":{"self":[{"href":"https:\/\/www.afmb.univ-mrs.fr\/en\/wp-json\/wp\/v2\/event\/7680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.afmb.univ-mrs.fr\/en\/wp-json\/wp\/v2\/event"}],"about":[{"href":"https:\/\/www.afmb.univ-mrs.fr\/en\/wp-json\/wp\/v2\/types\/event"}],"wp:attachment":[{"href":"https:\/\/www.afmb.univ-mrs.fr\/en\/wp-json\/wp\/v2\/media?parent=7680"}],"wp:term":[{"taxonomy":"events_category","embeddable":true,"href":"https:\/\/www.afmb.univ-mrs.fr\/en\/wp-json\/wp\/v2\/events_category?post=7680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}